Challenges in IFD Management: Forward-Thinking Strategies is an enduring activity based on content presented at 2015 MSG-ERC symposia at ICAAC/ICC and ID Week. The activity is designed to provide top-line updates on invasive fungal disease (IFD) diagnostics and therapeutics as well as controversial/forward-looking topics in mycology reviewed in a panel-discussion format. The activity includes relevant, interactive case challenges that highlight practical aspects of IFD case, interdisciplinary management, as well as international perspectives on patient-care strategies.
Release Date: 1/13/2016
Expiration Date: 1/12/2017
Estimated Time to Complete the Activity: 2.5 hrs
Media: Text-based presentation, interactive
Much has changed recently in the field of antifungal therapy, including recent regulatory approvals of new antifungal therapies/formulations and diagnostics. Moreover, epidemiologic trends, particularly development of resistance, add to the challenges of managing IFIs. With increasing complexity, there is a greater need for multidisciplinary care and expert advice about how to individualize therapy. This content, drawn from 2015 MSG-ERC activities at ICAAC and ID Week, focuses on both practical, day-to-day issues in antifungal management as well as future trends and controversies. The menu-driven format, which includes case applications where appropriate, allows you to select the topics that are most relevant to you in your practice.
After completing this activity, the participants should be better able to:
This activity is directed to physicians who specialize in infectious diseases, hematology/oncology, critical care, transplant, and pediatrics as well as other healthcare providers involved in the management of invasive mycoses.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Medical Education; Terranova Medica, LLC.
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All faculty, planning committee members and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in these activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
The following indicates the disclosure declaration information and the nature of those commercial relationships:
GEORGE R. THOMPSON, III, MD, FACP
RESEARCH SUPPORT:
Astellas; Merck & Co, Inc; Wako Diagnostics
ADVISORY BOARD:
Astellas
DATA REVIEW COMMITTEE/PANEL:
Astellas
LUIS OSTROSKY-ZEICHNER, MD, FACP, FIDSA, FSHEA
RESEARCH SUPPORT:
Astellas; Pfizer, Inc.; Scynexis
ADVISORY BOARD:
Merck & Co, Inc.
CONSULTANT:
Astellas; Scynexis
SPEAKER’S BUREAU:
Merck & Co, Inc.; Pfizer, Inc.; T2 Biosystems
INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURE:
Discussion of investigational agents and diagnostics for IFIs
ERIC J. BOW, MD, MSC, D. BACTERIOL, FRCPC
RESEARCH SUPPORT:
Astellas; Gilead Sciences; Gly-Pharma; Pfizer
ADVISORY BOARD/CONSULTANT:
Astellas
INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURE:
Discussion of investigational agents and diagnostics for IFIs
MELISSA D. JOHNSON, PHARMD
RESEARCH SUPPORT:
Astellas; Charles River Laboratories; World Health Information Science Consultants
ADVISORY BOARD/CONSULTANT:
Astellas
LOIS COLBURN
UNMC Center for Continuing Education
No conflicts to disclose.
BRENDA C. RAM, CMP, CCMEP
UNMC Center for Continuing Education
No conflicts to disclose.
ALISON FREIFELD, MD
University of Nebraska Medical Center
DATA SAFETY MONITORING BOARD:
Astellas; Merck & Co., Inc.
LISA A. TUSHLA, PHD, H(ASCP)
Terranova Medica, LLC
No conflicts to disclose
To receive a CME certificate of participation, participants should:
To participate, you will need access to a computer (either MAC or PC), tablet, or smart phone, with a Chrome (version 22.0.1229.94 or greater) web browser, Firefox (version 3.6 or greater) web browser, Safari (version 6 or greater) web browser, or an Internet Explorer (version 8.0 or greater) web browser, JavaScript enabled, connected to the Internet (high speed connection preferred), and cookies MUST be enabled on your browser.
Terranova Medica, LLC, and UNMC CCE are committed to protecting the privacy of those who choose to participate in activities on funguscme.org. This information below describes our security policies for safeguarding personal information as well as the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of personal information
To earn CME credits using the website, the UNMC CCE requires submission of certain personally identifiable information. The required items include: first name, last name, degree, and e-mail address. These items are necessary to award and track the credits that participants may earn after completing the program. To obtain credit, learners must complete an evaluation of the CME activity. This information is used in a continuous improvement process to enhance the learning experience of future programs.
Terranova Medica, LLC, and UNMC CCE do not transfer, sell, or share personal information with outside parties. We will not disclose the information unless required in a legal proceeding.
The opinions or views expressed in this continuing education activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the University of Nebraska Medical Center, Center for Continuing Education; the Mycoses Study Group Education & Research Consortium; and Terranova Medica, LLC.
Healthcare professionals and other individuals should review and consider other publications and materials on the subject before relying solely upon the information contained within this educational activity.
There is no charge for this activity.
This activity is supported by independent educational grants from: Astellas; Merck & Co, Inc; Gilead Sciences Europe, Ltd.; T2 Biosystems; MiraVista Diagnostics; and Viracor-IBT Laboratories.
For further information you may also contact Tom Davis by telephone or fax at 877-276-4523 or by email at tdavis@terranovamedica.com.
Copyright ©2015 UNMC CCE; Terranova Medica, LLC; and MSG-ERC.
